Latest News

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

Conference examines HIV and methamphetamine use intersection among MSM and transgender communities.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

DOJ clarifies ADA protections for people with opioid use disorder against discrimination.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

Biden's SOTU addresses harm reduction, endorses MAT Act; limited HIV-specific programming focus.

Family support predicts treatment success; policy must address intimate partner violence and health outcomes.

MAT Act removes X-waiver requirements, expanding buprenorphine access especially in rural communities.

NIH issues RFAs for Harm Reduction Network; Biden agenda targets decriminalization and safe consumption.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Explores the personal toll of patient advocacy, examining burnout and the need to support advocates.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.

Restrictive Medicaid policies limit HCV treatment access through fibrosis restrictions and sobriety requirements.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.